Table 1. Baseline demographics and patient characteristics.
| N=19 | ||
|---|---|---|
|
| ||
| Characteristic | No. | % |
|
| ||
| Sex | ||
| Male | 10 | 53 |
| Female | 9 | 47 |
|
| ||
| Age, years | ||
| Median | 66 | |
| Range | 45-79 | |
|
| ||
| ECOG performance status | ||
| 0 | 15 | 34 |
| 1 | 4 | 66 |
|
| ||
| Previous lines of systemic therapies | ||
| Median | 1 | |
| Range | 0-3 | |
|
| ||
| Previous therapy | ||
| Chemotherapy | 9 | 47 |
| Radiotherapy | 4 | 21 |
| Somatostatin Analogue | 13 | 68 |
| Radioembolization | 2 | 11 |
| VEGF-targeting antibody | 3 | 16 |
| Interferon Therapy | 1 | 5 |
| Surgery | 8 | 42 |
|
| ||
| NET origin | ||
| Pancreatic | 4 | |
| Small Bowel | 6 | |
| Lung | 4 | |
| Kidney | 1 | |
| Other / Unknown | 4 | |
|
| ||
| Functional Status | ||
| Functional | 6 | |
| Non-functional | 13 | |
|
| ||
| Number of metastatic Sites | ||
| 1 | 5 | |
| 2 | 8 | |
| 2+ | 6 | |
|
| ||
| Time from diagnosis | ||
| Median | 18 | |
| Mean | 38 | |
|
| ||
| Serum Chromogranin levels | ||
| 2× – 4× ULN | 3 | |
| >4× ULN | 10 | |
Abbreviations: ECOG, Eastern Cooperative Oncology Group; VEGF, vascular endothelial growth factor;